SCHEMBL2317675

SCHEMBL2317675

CS(=O)(=O)Nc1cccc(Cl)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.57
PTGS2 P35354 1/20 0.57
KEAP1 Q14145 1/20 0.57
ALDH1A1 P00352 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
TAAR1 Q96RJ0 1/20 0.54
KIF11 P52732 1/20 0.53
POLB P06746 1/20 0.53
PKM P14618 2/20 0.53
CYP1A2 P05177 1/20 0.53
CYP3A4 P08684 1/20 0.53
TSHR P16473 1/20 0.53
CYP2C19 P33261 1/20 0.53
PGR P06401 1/20 0.51
KMT2A Q03164 4/20 0.51
MEN1 O00255 3/20 0.51
ALOX15 P16050 1/20 0.51
LMNA P02545 2/20 0.50
MAPT P10636 2/20 0.50
CYP19A1 P11511 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL698855 0.85 KEAP1 (0.70) KEAP1ALDH1A1SMN1; SMN2KIF11POLB
SCHEMBL27574325 0.82 KMT2A (0.57) ALDH1A1SMN1; SMN2TAAR1PKMCYP1A2
SCHEMBL23541117 0.81 ALOX15 (0.56) ALDH1A1SMN1; SMN2TAAR1PKMCYP1A2
SCHEMBL22032846 0.80 SMN1; SMN2 (0.60) ALDH1A1SMN1; SMN2POLBKMT2AMEN1
SCHEMBL1644131 0.80 CA1 (0.59) ALDH1A1TAAR1PKMCYP1A2CYP3A4
SCHEMBL3995588 0.79 CTPS1 (0.51) PTGS1PTGS2ALDH1A1SMN1; SMN2TAAR1
SCHEMBL3379995 0.79 PGR (0.51) KIF11PKMPGR
SCHEMBL11239744 0.79 ALDH1A1 (0.61) PTGS1PTGS2KEAP1ALDH1A1SMN1; SMN2
SCHEMBL3784731 0.79 ALDH1A1 (0.55) PTGS1PTGS2KEAP1ALDH1A1SMN1; SMN2
SCHEMBL16574001 0.78 BRD4 (0.55) ALDH1A1KIF11PKMCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114181187-A Preparation method of 4-methanesulfonamido butyramide compound 上海应用技术大学 2022-03-15 CN claimed
US-20230348441-A1 BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR MEDSHINE DISCOVERY INC. (CN) 2023-11-02 US disclosed
EP-3328843-B1 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP (KR) 2022-10-26 EP disclosed
CN-114181187-A Preparation method of 4-methanesulfonamido butyramide compound 上海应用技术大学 2022-03-15 CN disclosed
CN-107922362-B 1,3, 4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same 株式会社钟根堂 2021-06-15 CN disclosed
WO-2021047674-A1 BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR 南京明德新药研发有限公司 2021-03-18 WO disclosed
EP-2772480-B2 HIV REPLICATION INHIBITOR SHIONOGI & CO (JP) 2020-12-09 EP disclosed
WO-2020159889-A1 SREBP INHIBITORS COMPRISING A THIOPHENE CENTRAL RING CAPULUS THERAPEUTICS, LLC (US) 2020-08-06 WO disclosed
US-20200172473-A1 DUAL MODULATORS OF FARNESOID X RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE JOHANN WOLFGANG GOETHE-UNIVERSITAET FRANKFURT AM MAIN (DE) 2020-06-04 US disclosed
EP-3630085-A1 DUAL MODULATORS OF FARNESOID X RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE Johann Wolfgang Goethe-Universität Frankfurt am Main (DE) 2020-04-08 EP disclosed
EP-3328843-A1 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2018-06-06 EP disclosed
EP-2772480-B1 HIV REPLICATION INHIBITOR SHIONOGI & CO (JP) 2018-05-23 EP disclosed
WO-2017018803-A1 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2017-02-02 WO disclosed
WO-2017018803-A1 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2017-02-02 WO disclosed
US-9199959-B2 HIV replication inhibitor SHIONOGI & CO., LTD. (JP) 2015-12-01 US disclosed
US-20140249306-A1 HIV REPLICATION INHIBITOR SHIONOGI & CO., LTD. (JP) 2014-09-04 US disclosed
US-8735387-B2 Oxazolopyrimidines as Edg-1 receptor agonists SANOFI (FR) 2014-05-27 US disclosed
US-20110190490-A1 OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS SANOFI-AVENTIS (FR) 2011-08-04 US disclosed
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND SUMITOMO CHEMICAL COMPANY LIMITED (JP) 2010-04-08 US disclosed
EP-1914221-A1 PROCESS FOR PRODUCING BIARYL COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-04-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348441-A1 BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR CRBN, CRKL, NCOR1 PTGS1 4353/4885PTGS2 4449/4885KEAP1 1226/4885
US-20110190490-A1 OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS EDNRA, OXGR1, EDF1 PTGS1 199/4885PTGS2 606/4885KEAP1 2269/4885
US-20200172473-A1 DUAL MODULATORS OF FARNESOID X RECEPTOR AND SOLUBLE EPOXIDE HYDROLASE NR1H4, NR1H3, NR1H2 PTGS1 259/4885PTGS2 236/4885KEAP1 295/4885
US-20100087680-A1 METHOD FOR PRODUCING BIARYL COMPOUND NISCH, BLVRB, BBOX1 PTGS1 4583/4885PTGS2 3544/4885KEAP1 1245/4885
US-20140249306-A1 HIV REPLICATION INHIBITOR SSU72, RTF2, ZC3HAV1 PTGS1 3702/4885PTGS2 3922/4885KEAP1 2632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.